研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Geneplus-Beijing Co. Ltd.[3]Chinese Cooperative Group of Liver Cancer (CCGLC)
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE), lenvatinib, and anti-PD-1/ PD-L1 antibody for patients with advanced intrahepatic cholangiocarcinoma who were initially unsuitable for the radical therapy, including resection, transplantation, or ablation.
